Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
- PMID: 8638406
- DOI: 10.1006/viro.1996.0266
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
Abstract
Reduced sensitivity of human immunodeficiency virus type 1 (HIV-1) to protease inhibitors is associated with multiple amino acid substitutions in the virus-encoded protease. The combination of changes that contribute to drug resistance is dependent in part upon the amino acid residues comprising protease alleles prior to drug therapy. We analyzed within peripheral blood mononuclear cells from HIV-1-infected mothers and their children viral gag/pol regions, which included p7, transframe p6/p6*, and protease coding sequences, as well as six protease cleavage sites. Sixty protease alleles from 12 individuals differed by at least 3 to as many as 10 amino acids from proteases encoded by molecular clones of HIV-1, indicating that there is no prototype or consensus wild-type HIV-1 protease sequence. Protease variants with a proline at position 63, a substitution associated with resistance to protease inhibitors, appeared in the absence of antiprotease therapy in 7 patients and were transmitted by 2 mothers to their infants. Gag p7 p6 regions were significantly more variable than protease. The p6/p6* region contained length variants and amino acid repeats in both reading frames. Five protease cleavage sites (B, D', D, E, and F) contained highly conserved amino acid sequences in individuals infected by epidemiologically distinct viruses. In contrast, C cleavage sites, localized between Gag p2 and Gag p7, displayed considerable amino acid variability, were unique among groups of infected individuals, and appeared to be related to particular protease alleles. Genetic variability in vivo in protease, in cleavage sites, and in proteins upstream of protease provides the potential to modulate enzyme activity and susceptibility to protease inhibitors.
Similar articles
-
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.Virology. 2002 Jan 5;292(1):137-49. doi: 10.1006/viro.2001.1184. Virology. 2002. PMID: 11878916
-
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.Antivir Ther. 2006;11(7):879-87. Antivir Ther. 2006. PMID: 17302250
-
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):487-97. doi: 10.1089/08892220151126526. AIDS Res Hum Retroviruses. 2001. PMID: 11350662
-
Human Immunodeficiency Virus Gag and protease: partners in resistance.Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63. Retrovirology. 2012. PMID: 22867298 Free PMC article. Review.
-
Expression systems for retroviral proteases.Methods Enzymol. 1994;241:3-16. doi: 10.1016/0076-6879(94)41055-0. Methods Enzymol. 1994. PMID: 7854184 Review. No abstract available.
Cited by
-
Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.Immunol Res. 2008;40(3):271-86. doi: 10.1007/s12026-007-0031-1. Immunol Res. 2008. PMID: 17952387
-
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.J Virol. 2000 May;74(10):4621-33. doi: 10.1128/jvi.74.10.4621-4633.2000. J Virol. 2000. PMID: 10775598 Free PMC article.
-
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.J Virol. 2005 Aug;79(16):10638-49. doi: 10.1128/JVI.79.16.10638-10649.2005. J Virol. 2005. PMID: 16051856 Free PMC article.
-
Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.ACS Infect Dis. 2019 Feb 8;5(2):316-325. doi: 10.1021/acsinfecdis.8b00336. Epub 2018 Dec 31. ACS Infect Dis. 2019. PMID: 30543749 Free PMC article.
-
Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Virology. 2008 Sep 1;378(2):272-81. doi: 10.1016/j.virol.2008.05.029. Epub 2008 Jul 2. Virology. 2008. PMID: 18599104 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials